How big is the Non-Alcoholic Fatty Liver Disease Market?

The Non-Alcoholic Fatty Liver Disease Market size is expected to reach USD 21.36 billion in 2024 and grow at a CAGR of 9.56% to reach USD 33.72 billion by 2029. Read More

What is the current Non-Alcoholic Fatty Liver Disease Market size?

In 2024, the Non-Alcoholic Fatty Liver Disease Market size is expected to reach USD 21.36 billion. Read More

Who are the key players in Non-Alcoholic Fatty Liver Disease Market?

Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk A/S, Gilead Sciences, Inc. and AbbVie, Inc. are the major companies operating in the Non-Alcoholic Fatty Liver Disease Market. Read More

Which is the fastest growing region in Non-Alcoholic Fatty Liver Disease Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Non-Alcoholic Fatty Liver Disease Market?

In 2024, the North America accounts for the largest market share in Non-Alcoholic Fatty Liver Disease Market. Read More

What years does this Non-Alcoholic Fatty Liver Disease Market cover, and what was the market size in 2023?

In 2023, the Non-Alcoholic Fatty Liver Disease Market size was estimated at USD 19.32 billion. The report covers the Non-Alcoholic Fatty Liver Disease Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Non-Alcoholic Fatty Liver Disease Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Non-Alcoholic Fatty Liver Disease (NAFLD)Companies

This report lists the top Non-Alcoholic Fatty Liver Disease (NAFLD) companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Non-Alcoholic Fatty Liver Disease (NAFLD) industry.